These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21124036)

  • 1. Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs.
    Eisele L; Günther F; Ebeling P; Nabring J; Dührsen U; Dürig J
    Onkologie; 2010; 33(12):658-64. PubMed ID: 21124036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.
    Girmenia C; Alimena G; Latagliata R; Morano SG; Celesti F; Coppola L; Spadea A; Tosti S; Mecarocci S; D'Elia GM; Tafuri A; Cimino G; Mandelli F
    Haematologica; 1999 Sep; 84(9):814-9. PubMed ID: 10477455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
    Gillis S; Dann EJ; Rund D
    Am J Hematol; 1996 Jan; 51(1):26-31. PubMed ID: 8571934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
    Saini L; Minden MD; Schuh AC; Yee KW; Schimmer AD; Gupta V; Atenafu EG; Murray C; Nixon S; Brandwein JM
    Am J Hematol; 2012 Mar; 87(3):323-6. PubMed ID: 22213349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
    Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
    J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toxicity of different treatment protocols for acute myeloid leukemias in adults: the results of four Russian multicenter studies].
    Parovichnikova EN; Savchenko VG; Kliasova GA; Isaev VG; Sokolov AN; Kulikov SM; Ustinova EN; Gribanova EO; Ryzhko VV; Khoroshko ND; Kravchenko SK; Galstian GM; Konstantinova TS; Zagoskina TP; Ziuzgin IS; Kaplanov KD; Moskov VI; Sokolova IV; Anchukova LV; Lapin VA; Loginov AB; Tumakov VA; Korobkin AV; Miliutina GI; Samoĭlova OS; Tikunova TS; Pristupa AS; Kondakova EV; Domnikova NP; Gavrilova LV; Obidina NA; Porokhina OV; Rekhtman GB; Mashchuk VN; Khuazheva NK; Kaporskaia TS; Golubeva ME; Maksimov AG; Ploskikh MA; Men'shakova SN; Mal'tsev VI; Rossiev VA; Pilipenko GI
    Ter Arkh; 2010; 82(7):5-11. PubMed ID: 20853602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
    Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse and death during first remission in acute myeloid leukemia.
    Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E
    Haematologica; 2008 Apr; 93(4):633-4. PubMed ID: 18379012
    [No Abstract]   [Full Text] [Related]  

  • 14. [Short-term intensive consolidation chemotherapy in the treatment of acute non-lymphocytic leukemia].
    Nagata K; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
    Gan To Kagaku Ryoho; 1992 Jul; 19(7):1079-81. PubMed ID: 1626944
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
    Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.